Polycythemia vera: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Michael Benjamin
No edit summary
imported>Thomas E Kelly
No edit summary
Line 10: Line 10:


[[Category: CZ Live]]
[[Category: CZ Live]]
[[Category: Health Sciences Workgroup]]

Revision as of 11:12, 25 February 2007

Clinical criteria

JAK2 mutations

[1], specifically at the V617F locus, give rise to myeloproliferative disorders such as essential thrombocythemia and polycythemia vera.

Authors [2] that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype.

[3]Scott, et al. New Engl J Med 356: 459-468 2007. [4]James, et al. Nature 434:1144-8 2005.

  1. Mutations in the JAK2 gene
  2. reported
  3. Cite error: Invalid <ref> tag; no text was provided for refs named Scott
  4. Cite error: Invalid <ref> tag; no text was provided for refs named James